

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6520595

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MARZENA MAZUR	01/07/2021
GLEB ANDRYIANAU	01/11/2021
LUKASZ JOACHIMIAK	01/07/2021
WOJCIECH CZESTKOWSKI	01/07/2021
MICHAL L. KOWALSKI	01/11/2021
PIOTR NIEDZIEJKO	01/11/2021
SYLWIA OLEJNICZAK	01/07/2021
KRZYSZTOF MATYSZEWSKI	01/07/2021
ROBERT KORALEWSKI	01/07/2021
JACEK P. OLCZAK	01/08/2021
ADAM A. GOLEBIOWSKI	01/09/2021
AGNIESZKA BARTOSZEWICZ	01/11/2021
RECEIVING PARTY DATA	
Name:	ONCOARENDI THERAPEUTICS S.A.
Street Address:	ZWIRKI I WIGURY 101
City:	WARSAW
State/Country:	POLAND
Postal Code:	02-089
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16929893
CORRESPONDENCE DATA	
Fax Number:	(212)484-3990
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2124843900
Email:	patentdocket@arentfox.com, scott.dodge@arentfox.com
Correspondent Name:	ARENT FOX LLP
Address Line 1:	1301 AVENUE OF THE AMERICAS
Address Line 4:	NEW YORK, NEW YORK 10019

PATENT

ATTORNEY DOCKET NUMBER:	038581.00054
NAME OF SUBMITTER:	SCOTT DODGE
SIGNATURE:	/Scott Dodge/
DATE SIGNED:	01/28/2021
Total Attachments: 6 source=038581-00054_Assignment-as-filed_2021-01-28#page1.tif source=038581-00054_Assignment-as-filed_2021-01-28#page2.tif source=038581-00054_Assignment-as-filed_2021-01-28#page3.tif source=038581-00054_Assignment-as-filed_2021-01-28#page4.tif source=038581-00054_Assignment-as-filed_2021-01-28#page5.tif source=038581-00054_Assignment-as-filed_2021-01-28#page6.tif	

ASSIGNMENT

WHEREAS, I/WE, **Marzena MAZUR**, a citizen of Poland,
residing at c/o OncoArendi Therapeutics S.A., Żwirki i Wigury 101,
02-089 Warszawa, Poland; and

Gleb ANDRYIANA, a citizen of Poland,
residing at Ul. Promenada 1/3, m. 9, 00-778 Warszawa, Poland; and

Lukasz JOACHIMIAK, a citizen of Poland,
residing at c/o OncoArendi Therapeutics S.A., Żwirki i Wigury 101,
02-089 Warszawa, Poland; and

Wojciech CZESTKOWSKI, a citizen of Poland,
residing at c/o OncoArendi Therapeutics S.A., Żwirki i Wigury 101,
02-089 Warszawa, Poland; and

Michał KOWALSKI, a citizen of Poland,
residing at c/o OncoArendi Therapeutics S.A., Żwirki i Wigury 101,
02-089 Warszawa, Poland; and

Piotr NIEDZIEJKO, a citizen of Poland,
residing at c/o OncoArendi Therapeutics S.A., Żwirki i Wigury 101,
02-089 Warszawa, Poland; and

Sylvia OLEJNICZAK, a citizen of Poland,
residing at c/o OncoArendi Therapeutics S.A., Żwirki i Wigury 101,
02-089 Warszawa, Poland; and

Krzysztof MATYSZEWSKI, a citizen of Poland,
residing at c/o OncoArendi Therapeutics S.A., Żwirki i Wigury 101,
02-089 Warszawa, Poland; and

Robert KORALEWSKI, a citizen of Poland,
residing at c/o OncoArendi Therapeutics S.A., Żwirki i Wigury 101,
02-089 Warszawa, Poland; and

Jacek OLCZAK, a citizen of Poland,
residing at c/o OncoArendi Therapeutics S.A., Żwirki i Wigury 101,
02-089 Warszawa, Poland; and

Adam GOLEBIOWSKI, a citizen of Poland,
residing at c/o OncoArendi Therapeutics S.A., Żwirki i Wigury 101,
02-089 Warszawa, Poland; and

Agnieszka BARTOSZEWICZ, a citizen of Poland,
residing at c/o OncoArendi Therapeutics S.A., Żwirki i Wigury 101,
02-089 Warszawa, Poland;

the foregoing parties alternatively and collectively denominated herein as the INVENTORS;

have invented certain new and useful improvements in

SUBSTITUTED AMINO TRIAZOLES USEFUL AS CHITINASE INHIBITORS

(hereinafter called “the Invention”) for which a Provisional Application for a Patent in the United States was filed on **15 July 2019**, and was accorded U.S. Serial No. US62/874,108 (“the US Provisional Application”) and for which a Polish National Patent Application was filed on **15 July 2019** and was accorded PL Serial no. P-430586 (“the Polish Patent Application”); and

WHEREAS, the INVENTORS filed an Application for Letters Patent in the United States on **15 July 2020**, which was accorded U.S. Serial No. US16/929,893 (“The US Non-Provisional Application”); and

WHEREAS,

OncoArendi Therapeutics S.A.
with an office at
Żwirki i Wigury 101, 02-089 Warszawa, Poland,

ASSIGNEE, is desirous of obtaining the entire right, title and interest in, to and under the said Invention and the said US Non-Provisional application;

NOW, THEREFORE, for other good and valuable consideration, the receipt of which is hereby acknowledged, we the said

Marzena MAZUR
Gleb ANDRYIANAU
Lukasz JOACHIMIAK
Wojciech CZESTKOWSKI
Michał KOWALSKI
Piotr NIEDZIEJKO
Sylwia OLEJNICZAK
Krzysztof MATYSZEWSKI
Robert KORALEWSKI
Jacek OLCZAK
Adam GOLEBIOWSKI
Agnieszka BARTOSZEWICZ

have sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over, to the said

OncoArendi Therapeutics S.A.,

its successors, legal representatives and assigns, the entire right, title and interest in, to and under the said Invention and the said US Non-Provisional Application and all divisions, renewals, and continuations thereof, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof, and all applications for Letters Patent which may hereafter be filed for said Invention in any country or countries foreign to the United States, the right to claim priority under the terms of any appropriate International Convention based upon said US Non-Provisional Application, and all Letters Patent which may be granted from said Invention in any country or countries foreign to the United States and extensions, renewals and reissues thereof; and including the right to sue for past infringement; and we hereby authorize and request the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States, whose duty is to issue patents on applications as aforesaid, to issue all Letters Patent for said Invention to the said

OncoArendi Therapeutics S.A.,

it successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND WE HEREBY covenant that we have full right to convey the interest herein assigned in the manner hereinabove set forth, and that we have not executed, and will not execute, any agreement in conflict herewith.

AND WE HEREBY further covenant and agree that we will communicate to the said

OncoArendi Therapeutics S.A.,

its successors, legal representatives and assigns, any fact known to us respecting said Invention, and testify in any legal proceeding, sign all lawful papers, execute all divisions, continuing and reissue applications, make all rightful oaths and generally do everything possible to aid the said

OncoArendi Therapeutics S.A.,

its successors, legal representatives and assigns, to obtain and enforce proper Patent Protection for said Invention in the United States.

IN TESTIMONY WHEREOF, We hereunto set our hand and seal the day and year set opposite our signature.

Date _____

Marzena MAZUR

Date _____

Gleb ANDRYIANAU

Date _____

Lukasz JOACHIMIAK

Date _____

Wojciech CZESTKOWSKI

Date _____

Michał KOWALSKI

Date _____

Piotr NIEDZIEJKO

Date _____

Sylwia OLEJNICZAK

Date _____

Krzysztof MATYSZEWSKI

Date _____

Robert KORALEWSKI

Date _____

Jacek OLCZAK

Date Jan 9th, 2021

Adam Golebiowski
Adam GOLEBIOWSKI

Date _____

Agnieszka BARTOSZEWICZ

Date _____

OncoArendi Therapeutics S.A.


By: _____

Title: _____

Date _____

Marzena MAZUR

Date 11.7.2021


Gleb ANDRYIANAU


Date _____

Lukasz JOACHIMIAK


Date _____

Wojciech CZESTKOWSKI

Date 11/01/2021


Michał KOWALSKI

Date 11/01/2021


Piotr NIEDZIEJKO

Date _____

Sylvia OLEJNICZAK

Date _____

Krzysztof MATYSZEWSKI

Date _____

Robert KORALEWSKI

Date _____

Jacek OLCZAK

Date _____


Adam GOLEBIOWSKI

Date 11/01/2021


Agnieszka BARTOSZEWICZ

Date 11/01/2021

OncoArendi Therapeutics S.A.


By: Marcin Szumowski

Title: _____
President & CEO

Date 07.01.2021

Monika MOUR

Marzena MAZUR

Date _____

Gleb ANDRYIANAU

Date 07.01.2021

Lukasz Joachimiak

Lukasz JOACHIMIAK

Date 07.01.2021

Wojciech Czestkowski

Wojciech CZESTKOWSKI

Date _____

Michal KOWALSKI

Date _____

Piotr NIEDZIEJKO

Date 07.01.2021

Sylvia Olejniczak

Sylvia OLEJNICZAK

Date 07.01.2021

Krzysztof Matyszewski

Krzysztof MATYSZEWSKI

Date 07.2021

Robert Koralewski

Robert KORALEWSKI

Date 08.01.2021

Jacek Olczak

Jacek OLCZAK

Date _____

Adam GOLEBIOWSKI

Date _____

Agnieszka BARTOSZEWICZ

Date 11.01.2021

OncoArendi Therapeutics S.A.

By: Marcin Szumowski

Title: _____
President & CEO